Should I buy or sell AbCellera Biologics stock right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for AbCellera Biologics in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ABCL shares. View ABCL analyst ratings or view top-rated stocks .

What is AbCellera Biologics' stock price target for 2024?

7 equities research analysts have issued 1-year price targets for AbCellera Biologics' stock. Their ABCL share price targets range from $6.00 to $24.00. On average, they predict the company's stock price to reach $15.86 in the next year. This suggests a possible upside of 309.7% from the stock's current price. View analysts price targets for ABCL or view top-rated stocks among Wall Street analysts .

How have ABCL shares performed in 2024?

AbCellera Biologics' stock was trading at $5.71 at the beginning of the year. Since then, ABCL stock has decreased by 32.2% and is now trading at $3.87. View the best growth stocks for 2024 here .

When is AbCellera Biologics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 7th 2024. View our ABCL earnings forecast .

How can I listen to AbCellera Biologics' earnings call?

AbCellera Biologics will be holding an earnings conference call on Tuesday, May 7th at 5:00 PM Eastern. Interested parties can register for or listen to the call using this link .

How were AbCellera Biologics' earnings last quarter?

AbCellera Biologics Inc. (NASDAQ:ABCL) issued its quarterly earnings data on Tuesday, February, 20th. The company reported ($0.17) earnings per share for the quarter, missing analysts' consensus estimates of ($0.14) by $0.03. The firm had revenue of $9.18 million for the quarter, compared to the consensus estimate of $9.58 million. AbCellera Biologics had a negative trailing twelve-month return on equity of 12.36% and a negative net margin of 384.99%.

What ETFs hold AbCellera Biologics' stock?

ETFs with the largest weight of AbCellera Biologics (NASDAQ:ABCL) stock in their portfolio include Amplify Treatments, Testing and Advancements ETF (GERM) . TrueShares Technology, AI & Deep Learning ETF (LRNZ) .

When did AbCellera Biologics IPO?

AbCellera Biologics (ABCL) raised $356 million in an initial public offering on Friday, December 11th 2020. The company issued 23,000,000 shares at a price of $14.00-$17.00 per share. Credit Suisse, Stifel, Berenberg, SVB Leerink and BMO Capital Markets acted as the underwriters for the IPO.

Who are AbCellera Biologics' major shareholders?

AbCellera Biologics' stock is owned by many different retail and institutional investors. Top institutional investors include TrueMark Investments LLC (0.04%) and Pacifica Partners Inc. (0.00%). Insiders that own company stock include Andrew Booth , Andrew Lo , Carl L G Hansen , Holdings Ltd Thermopylae, John Hamer , John S Montalbano , Michael R Hayden and Veronique Lecault . View institutional ownership trends .

How do I buy shares of AbCellera Biologics?

Shares of ABCL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:ABCL

AbCellera Biologics (ABCL) Stock Price, News & Analysis

→ The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad)

Free ABCL Stock Alerts

$3.87

-0.04 (-1.02%)

(As of 04/19/2024 ET)

Compare

Today's Range: $3.79
▼
$3.96
50-Day Range: $3.87
▼
$5.46
52-Week Range: $3.79
▼
$8.05

Volume: 978,363 shs
Average Volume: 1.36 million shs
Market Capitalization: $1.13 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $15.86

Get AbCellera Biologics alerts:

AbCellera Biologics MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 309.7% Upside
$15.86 Price Target
Short Interest: Bearish
11.50% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: -0.49
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($0.66) to ($0.70) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.26 out of 5 stars

Medical Sector

734th out of 911 stocks

Pharmaceutical Preparations Industry

327th out of 411 stocks

3.5

Analyst's Opinion

Consensus Rating
AbCellera Biologics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
AbCellera Biologics has only been the subject of 2 research reports in the past 90 days.

0.0

Short Interest

Percentage of Shares Shorted
11.50% of the float of AbCellera Biologics has been sold short.
Short Interest Ratio / Days to Cover
AbCellera Biologics has a short interest ratio ("days to cover") of 16.7, which indicates bearish sentiment.
Change versus previous month
Short interest in AbCellera Biologics has recently increased by 2.39%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
AbCellera Biologics does not currently pay a dividend.
Dividend Growth
AbCellera Biologics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ABCL.

0.8

News and Social Media Coverage

News Sentiment
AbCellera Biologics has a news sentiment score of -0.49. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.52 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for AbCellera Biologics this week, compared to 2 articles on an average week.
Search Interest
Only 25 people have searched for ABCL on MarketBeat in the last 30 days. This is a decrease of -26% compared to the previous 30 days.
MarketBeat Follows
Only 15 people have added AbCellera Biologics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, AbCellera Biologics insiders have not sold or bought any company stock.
Percentage Held by Insiders
32.45% of the stock of AbCellera Biologics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
61.42% of the stock of AbCellera Biologics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for AbCellera Biologics are expected to decrease in the coming year, from ($0.66) to ($0.70) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of AbCellera Biologics is -7.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of AbCellera Biologics is -7.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
AbCellera Biologics has a P/B Ratio of 0.97. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Gold Safe Exchange

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

About AbCellera Biologics Stock (NASDAQ:ABCL)

AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; and a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets, as well as strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.

ABCL Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ABCL Stock News Headlines

April 20, 2024 | americanbankingnews.com

AbCellera Biologics (NASDAQ:ABCL) Hits New 1-Year Low at $3.84

April 18, 2024 | finance.yahoo.com

AbCellera Biologics Inc. (ABCL)

April 20, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

April 8, 2024 | businesswire.com

AbCellera Presents Data on T-Cell Engagers Against Four Tumor Targets at AACR 2024

April 3, 2024 | businesswire.com

AbCellera to Report First Quarter 2024 Financial Results on May 7, 2024

March 27, 2024 | investorplace.com

The 7 Best Penny Stocks to Buy in Q2 2024

March 27, 2024 | finance.yahoo.com

Billionaire Investor Stan Druckenmiller and Insiders Are Piling Into These 11 Stocks

March 19, 2024 | businesswire.com

AbCellera to Present at the Bloom Burton Healthcare Conference on April 16, 2024

April 20, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

March 11, 2024 | msn.com

AbCellera gains on antibody collaboration with Biogen

March 5, 2024 | businesswire.com

AbCellera Announces Four Presentations on T-Cell Engagers at AACR 2024

February 29, 2024 | finance.yahoo.com

After losing 38% in the past year, AbCellera Biologics Inc. (NASDAQ:ABCL) institutional owners must be relieved by the recent gain

February 28, 2024 | seekingalpha.com

AbCellera: Victim Of Its Own Success

February 26, 2024 | investorplace.com

3 Highly Rated Biotech Stocks to Buy for 300% Gains

February 23, 2024 | markets.businessinsider.com

Piper Sandler Reaffirms Their Buy Rating on AbCellera Biologics (ABCL)

February 23, 2024 | businesswire.com

AbCellera Announces Resignation of Board Member

February 23, 2024 | finance.yahoo.com

ABCL Mar 2024 4.000 call

February 23, 2024 | finance.yahoo.com

ABCL Mar 2024 5.000 call

February 23, 2024 | msn.com

Benchmark Upgrades AbCellera Biologics (ABCL)

February 22, 2024 | benzinga.com

AbCellera Biologics Stock (NASDAQ:ABCL) Earnings Dates and Earning Calls

February 22, 2024 | businesswire.com

AbCellera to Present at Upcoming Investor Conferences in March

February 22, 2024 | msn.com

Obesity drugs to expand U.S. GDP by 1% in the coming years: Goldman Sachs

February 22, 2024 | benzinga.com

AbCellera Biologics Stock (NASDAQ:ABCL) Insider Trades

February 22, 2024 | markets.businessinsider.com

Stifel Nicolaus Reaffirms Their Buy Rating on AbCellera Biologics (ABCL)

February 21, 2024 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Bicycle Therapeutics (BCYC), GeneDx Holdings (WGS) and Halozyme (HALO)

February 21, 2024 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Halozyme (HALO) and AbCellera Biologics (ABCL)

February 21, 2024 | finance.yahoo.com

Q4 2023 Abcellera Biologics Inc Earnings Call

See More Headlines

Receive ABCL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AbCellera Biologics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/20/2024
Today: 4/20/2024
Next Earnings (Confirmed): 5/07/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:ABCL
CUSIP: N/A
CIK: 1703057
Web: www.abcellera.com
Phone: 604-559-9005
Fax: N/A
Employees: 586
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $15.86
High Stock Price Target: $24.00
Low Stock Price Target: $6.00
Potential Upside/Downside: +309.7%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 7 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.52)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-146,400,000.00
Net Margins: -384.99%
Pretax Margin: -457.67%
Return on Equity: -12.36%
Return on Assets: -9.70%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 7.33
Quick Ratio: 7.33

Sales & Book Value

Annual Sales: $38.03 million
Price / Sales: 29.79
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $3.97 per share
Price / Book: 0.97

Miscellaneous

Outstanding Shares: 292,780,000
Free Float: 197,774,000
Market Cap: $1.13 billion
Optionable: Optionable
Beta: 0.36

10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

Dr. Carl L.G. Hansen Ph.D. (Age 49)
CEO, President & Chairperson
Comp: $711.47k
Mr. Andrew Booth M.B.A. (Age 50)
Chief Financial Officer
Comp: $642.42k
Dr. Veronique Lecault Ph.D. (Age 39)
COO & Director
Comp: $645.07k
Mr. Tryn T. Stimart Esq. (Age 54)
J.D., M.Sc., Chief Legal Officer, CCO, Compliance Officer, Corporate Secretary & Privacy Officer
Comp: $644.4k
Mr. Neil Aubuchon B.A. (Age 53)
M.B.A., Chief Commercial Officer
Comp: $684.81k
Marcie Thiessen CPA
CGA, Senior Director of Finance & Accounting
Dr. Ester Falconer Ph.D. (Age 49)
Chief Technology Officer
Kathleen Reid B.A.
Head of Corporate Communications
Graham Craig M.Sc.
Director of Corporate Development
Mr. Murray McCutcheon Ph.D.
Senior Vice President of Partnering

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

ABCL Stock Analysis - Frequently Asked Questions

Should I buy or sell AbCellera Biologics stock right now?: 7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for AbCellera Biologics in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ABCL shares.
View ABCL analyst ratings or view top-rated stocks.
What is AbCellera Biologics' stock price target for 2024?: 7 equities research analysts have issued 1-year price targets for AbCellera Biologics' stock. Their ABCL share price targets range from $6.00 to $24.00. On average, they predict the company's stock price to reach $15.86 in the next year. This suggests a possible upside of 309.7% from the stock's current price.
View analysts price targets for ABCL or view top-rated stocks among Wall Street analysts.
How have ABCL shares performed in 2024?: AbCellera Biologics' stock was trading at $5.71 at the beginning of the year. Since then, ABCL stock has decreased by 32.2% and is now trading at $3.87.
View the best growth stocks for 2024 here.
When is AbCellera Biologics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 7th 2024.
View our ABCL earnings forecast.
How can I listen to AbCellera Biologics' earnings call?: AbCellera Biologics will be holding an earnings conference call on Tuesday, May 7th at 5:00 PM Eastern. Interested parties can register for or listen to the call using this link.
How were AbCellera Biologics' earnings last quarter?: AbCellera Biologics Inc. (NASDAQ:ABCL) issued its quarterly earnings data on Tuesday, February, 20th. The company reported ($0.17) earnings per share for the quarter, missing analysts' consensus estimates of ($0.14) by $0.03. The firm had revenue of $9.18 million for the quarter, compared to the consensus estimate of $9.58 million. AbCellera Biologics had a negative trailing twelve-month return on equity of 12.36% and a negative net margin of 384.99%.

What ETFs hold AbCellera Biologics' stock?: ETFs with the largest weight of AbCellera Biologics (NASDAQ:ABCL) stock in their portfolio include Amplify Treatments, Testing and Advancements ETF (GERM).TrueShares Technology, AI & Deep Learning ETF (LRNZ).
When did AbCellera Biologics IPO?: AbCellera Biologics (ABCL) raised $356 million in an initial public offering on Friday, December 11th 2020. The company issued 23,000,000 shares at a price of $14.00-$17.00 per share. Credit Suisse, Stifel, Berenberg, SVB Leerink and BMO Capital Markets acted as the underwriters for the IPO.
Who are AbCellera Biologics' major shareholders?: AbCellera Biologics' stock is owned by many different retail and institutional investors. Top institutional investors include TrueMark Investments LLC (0.04%) and Pacifica Partners Inc. (0.00%). Insiders that own company stock include Andrew Booth, Andrew Lo, Carl L G Hansen, Holdings Ltd Thermopylae, John Hamer, John S Montalbano, Michael R Hayden and Veronique Lecault.
View institutional ownership trends.
How do I buy shares of AbCellera Biologics?: Shares of ABCL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ABCL) was last updated on 4/20/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

AbCellera Biologics (ABCL) Stock Price, News & Analysis

AbCellera Biologics MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About AbCellera Biologics Stock (NASDAQ:ABCL)

ABCL Stock Price History

ABCL Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

ABCL Stock Analysis - Frequently Asked Questions

Overall MarketRank^™